PRX 08066

Drug Profile

PRX 08066

Alternative Names: PRX-08066; PRX-8066

Latest Information Update: 30 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer Clinical Data
  • Class Antihypertensives; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension

Highest Development Phases

  • No development reported Pulmonary arterial hypertension

Most Recent Events

  • 30 Apr 2012 No development reported - Phase-II for Pulmonary hypertension in USA (PO)
  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 02 Nov 2010 PRX 08066 receives Orphan Drug status for Pulmonary arterial hypertension in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top